Edwards Lifesciences EW Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 312.9%-5.4pp | 314.6%-3.8pp | 316%-1.2pp | 317.6%-2.2pp | 318.3%-4.4pp | |
| Operating margin | 92.3%-12.8pp | 96.7%-8.5pp | 101.2%-5.9pp | 103.5%-6.1pp | 105.1%-6.6pp | |
| Net margin | 131.3%-128pp | 189.6%-21.2pp | 248.7%+86.6pp | 303.6%+185pp | 258.9%+136pp | |
| Returns | ||||||
| Return on equity | 81.3%-90.0pp | 119%-25.4pp | 158.6%+41.8pp | 196.1%+108pp | 171.3%+82.4pp | |
| Return on invested capital | 61%-15.8pp | 65.1%-13.0pp | 69.8%-10.6pp | 73.9%-4.6pp | 76.8%-0.4pp | |
| Efficiency | ||||||
| Asset turnover | 1.9×-0.1× | 1.9×-0.2× | 1.9×-0.2× | 1.9×-0.2× | 2×-0.1× | |
| Liquidity | ||||||
| Current ratio | 16.8×+1.0× | 16.9×+1.8× | 17.3×+3.0× | 16.8×+2.6× | 15.8×+2.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×0.0× | 0.3×-0.1× | 0.3×-0.1× | 0.3×-0.1× | 0.3×-0.1× | |
| Net debt / EBITDA | -5.6×0.0× | -6×-1.6× | -5.9×-2.8× | -6.6×-4.8× | -5.6×-4.1× | |
| Per Share | ||||||
| Book value per share | $70.79+13.8% | $70.24+23.8% | $69.28+35.9% | $67.81+47.7% | $62.18+41.1% | |
| Valuation | ||||||
| Market capitalization | $185.79B+2.3% | $182.08B-7.4% | $176.27B-11.5% | $170.36B-15.5% | $181.53B-10.6% | |
| Price / earnings | 132.3×+64.3× | 100.3×+1.9× | 64.7×-56.3× | 40.9×-100.0× | 68×-76.3× | |
| Price / sales | 31.1×-2.8× | 31.4×-6.0× | 31.3×-7.3× | 31×-10.2× | 33.9×-10.1× | |
| Price / book | 17.9×-2.3× | 17.7×-6.4× | 17.3×-9.4× | 16.9×-11.9× | 20.2×-10.1× | |
| EV / EBITDA | 116.2×+5.7× | 112.1×-11.7× | 105.7×-21.4× | 101.7×-32.4× | 110.4×-29.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Edwards Lifesciences's profit margins?
- Edwards Lifesciences (EW) runs a 77.9% gross margin and a 21.4% operating margin, with a 17.4% net margin.
- Where do Edwards Lifesciences's ratios come from?
- Every ratio is computed from Edwards Lifesciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
